Pseudophakic cystoid macular edema (CMO) known to appear in 0.1-2.35% of patients after phacoemulsification is one of the common causes of vision decrease during postoperative period. The authors analyzed a case of CMO development in a pseudophakic patient diagnosed 7 months after uncomplicated phacoemulsification. Optical coherence tomography (OCT) was suggested for patients with low vision and a sensation of shroud before the eye for early diagnosis of pathological process. Intravitreal injection of the 0.7 mg dexamethasone micro-implant performed soon after establishing the diagnosis was proved to be viable for postoperative CMO arrest in patients without previous treatment. One month after intravitreal implant injection, the visual acuity in the patient's eye improved from 0.4 to 0.7, and retinal thickness in the macular area decreased from 705 to 255 μm. The result remained stable for 10 months. Intravitreal micro-implant appeared to have higher efficiency in contrast with traditional treatment methods (according to literature data), which was attributed to direct drug delivery to the area of pathological process. The use of 0.7 mg dexamethasone implant did not increase the intraocular pressure indicating its potential viability for patients with compensated glaucoma.

Псевдофакический кистозный макулярный отек (КМО), или синдром Ирвина-Гасса,-одна из распространенных причин снижения зрения даже после неосложненного хирургического лечения катаракты. По данным литературы, частота КМО после современной факоэмульсификации составляет 0,1-2,35% [1]. Чаще всего КМО развивается через 4-6 нед после экстракции катаракты, но описаны случаи его возникновения и в более поздние сроки после операции [1, 2]. Патогенез КМО многофакторный, но основной причиной осложнения считается послеоперационное воспаление [3-5]. Воспалительные медиаторы

No abstract

We analysed the effect of prostoglandins analogues application on the course of postoperative period of cataract phakoemulsification in 58patients with primary open-angle glaucoma. All patients before the operation had normal intraocular pressure (on average 15.6±0.07mm Hg), the optical coherent tomography showed normal parameters of retina thickness in 1mm zone and the macula volume in 6mm zone. Instillation of nonsteroid anti-inflammatory drug after the operation lasted 6–8weeks, and prostoglandins analogues continued to be instillated during all period of observation. The course of the early postoperative period was areactive. Average visual acuity on the first day was 0.69±0.05, in 6–8 weeks – 0.85±0.05. The average level of intaocular pressure during application of prostoglandins analogues on first day was 16.9±0.37mm Hg, and in 6–8weeks – 15.1±0.28mm Hg. Optical coherence tomography revealed little change of retina thickness and macular area volume before the operation and in 6–8weeks after it was regarded as an error of measurement method.Thus, continuation of instillations of prostoglandins analogues in pre- and postoperative period in uncomplicated phakoemulsification in patients with primary open-angle glaucoma promote continuity in treatment, support com-plience and provide stable intraocular pressure without the expressed reactive hypertensia. Application of nonsteroid anti-inflammatory drug during 6–8 weeks after phakoemulsification in patients with primary open-angle glaucoma serves as an effective measure of prevention of inflammation of an anterior and posterior eye segment during pros-toglandins analogues treatrment.

No abstract